The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis
Abstract
Background Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied. Objective To perform a cost-utility analysis of the effects of aspirin therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the primary prevention of CHD events in men. Design Markov model. Data sources Published literature. Target population Middle-aged men without a history of cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 15%, and 25%). Time horizon Lifetime. Perspective Third-party payer. Interventions Low-dose aspirin, a statin, both drugs as combination therapy, or no therapy. Outcome measure Cost per quality-adjusted life-year gained. Results of base-case analysis For 45-year-old men who do not smoke, are not hypertensive, and have a 10-year risk for CHD of 7.5%, aspirin was more effective and less costly than no treatment. The addition of a statin to aspirin therapy produced an incremental cost-utility ratio of 56,200 dollars per quality-adjusted life-year gained compared with aspirin alone. Results of sensitivity analysis Excess risk for hemorrhagic stroke and gastrointestinal bleeding with aspirin, risk for CHD, the cost of statins, and the disutility of taking medication had important effects on the cost-utility ratios. Limitations Several input parameters, particularly adverse event rates and utility values, are supported by limited empirical…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, for adults with ASCVD risk >1% per year, the number of ASCVD events prevented will be similar to the number of episodes of bleeding induced, although these complications do not have equal effects on longterm health (182).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [182]
In the citing paper
“However, for adults with ASCVD risk >1% per year, the number of ASCVD events prevented will be similar to the number of episodes of bleeding induced, although these complications do not have equal effects on long-term health (176).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [176]
In the citing paper
“Thus, aspirin appears to have a modest effect on ischemic vascular events, with the absolute decrease in events depending on the underlying ASCVD risk.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [176]
In the citing paper
“The main adverse effect is an increased risk of gastrointestinal bleeding.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [176]
In the citing paper
“The excess risk may be as high as 5 per 1,000 per year in real-world settings.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [176]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236 · cited 2×
“The Editors ArticlePrimary Prevention of Coronary Heart Disease Events in Men www.annals.org 7 March 2006 Annals of Internal Medicine Volume 144 • Number 5 327 1) was drawn from population-based studies in the United Kingdom (12, 16) and applied to the general mortality rates from the U.S. life tables to generate the…”
MethodCardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,854 · cited 3×
“Rational use of these therapies can be improved if providers assess risk for CHD in all middle-aged and older adults and in younger adults with additional risk factors, as recommended by the American Heart Association (4).”
BackgroundEffect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147
Siegel, J. E. (1996) · JAMA · doi:10.1001/jama.276.16.1339 · Cited by 1,037 · cited 1×
“All costs and outcomes were discounted at 3% in accordance with current consensus recommendations (8).”
Method
Research works printed but not linked: 6
- Murphy M, 2002, Clin Evid, 91
- Minino AM, 2001, Natl Vital Stat Rep, 49, 1
- Sudlow C, 2001, Practitioner, 245, 859
- Chen Q, 2000, Inquiry, 37, 359
- Troche CJ, 1998, Eur Heart J, 19, C59
- 10.1001/jama.285.19.2486 · DOI · Paper page
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“In adults with CVD risk greater than 1% per year, the number of CVD events prevented will be similar to or greater than the number of episodes of bleeding induced, although these complications do not have equal effects on long-term health (384).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“In adults with CVD risk greater than 1% per year, the number of CVD events prevented will be similar to or greater than the number of episodes of bleeding induced, although these complications do not have equal effects on long-term health (314).”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“1% per year, the number of CVD events prevented will be similar to or greater than the number of episodes of bleeding induced, although these complications do not have equal effects on longterm health (274).”
Background
Metadata
- Authors
- Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2006-03-07
- Volume
- 144
- Issue
- 5
- Pages
- 326-336
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2010518325
- Cited by
- 204
- References
- 50
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 6 · 2017: 10 · 2016: 7 · 2015: 16 · 2014: 14 · 2013: 13 · 2012: 10
- FWCI
- 17.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCLA - Biblioteca de Ciencias de la Salud (submittedVersion)
- Funders
- Centers for Disease Control and Prevention (1p30cd000138-01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- aspirin, statins, combination therapy, primary prevention, coronary artery disease, cost-utility analysis, middle-aged men, 10-year cardiovascular risk, quality-adjusted life years, hemorrhagic stroke, gastrointestinal bleeding
- MeSH terms
- Aspirin, Computer Simulation, Coronary Disease, Cost-Benefit Analysis, Drug Therapy, Combination, Fibrinolytic Agents, Gastrointestinal Hemorrhage, Humans, Male, Markov Chains, Middle Aged, Primary Prevention, Risk Factors, Sensitivity and Specificity, Drug Costs, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-144-5-200603070-00007
- The paper
- Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006). Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-144-5-200603070-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.